CA3009983A1 - Lyposomal wnt3a for use in treating tooth sensitivity - Google Patents

Lyposomal wnt3a for use in treating tooth sensitivity Download PDF

Info

Publication number
CA3009983A1
CA3009983A1 CA3009983A CA3009983A CA3009983A1 CA 3009983 A1 CA3009983 A1 CA 3009983A1 CA 3009983 A CA3009983 A CA 3009983A CA 3009983 A CA3009983 A CA 3009983A CA 3009983 A1 CA3009983 A1 CA 3009983A1
Authority
CA
Canada
Prior art keywords
wnt
pulp
dentin
agent
tooth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3009983A
Other languages
English (en)
French (fr)
Inventor
Jill Helms
Daniel J. Hunter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA3009983A1 publication Critical patent/CA3009983A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/50—Preparations specially adapted for dental root treatment
    • A61K6/58—Preparations specially adapted for dental root treatment specially adapted for dental implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
    • A61K6/69—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3009983A 2014-12-29 2015-12-28 Lyposomal wnt3a for use in treating tooth sensitivity Pending CA3009983A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462097502P 2014-12-29 2014-12-29
US62/097,502 2014-12-29
PCT/US2015/067683 WO2016109433A1 (en) 2014-12-29 2015-12-28 Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production

Publications (1)

Publication Number Publication Date
CA3009983A1 true CA3009983A1 (en) 2016-07-07

Family

ID=56284970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3009983A Pending CA3009983A1 (en) 2014-12-29 2015-12-28 Lyposomal wnt3a for use in treating tooth sensitivity

Country Status (6)

Country Link
US (2) US10512668B2 (enExample)
EP (1) EP3240562B1 (enExample)
JP (1) JP6887948B2 (enExample)
AU (1) AU2015374240B2 (enExample)
CA (1) CA3009983A1 (enExample)
WO (1) WO2016109433A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201617820D0 (en) * 2016-10-21 2016-12-07 King S College London Dental treatment
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递系统的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1868689T3 (pl) * 2005-03-21 2015-10-30 Glaxo Group Ltd Wolna od alkilosiarczanu i wolna od ortofosforanu kompozycja do czyszczenia zębów zawierająca źródło fluorku i krzemionkowe ścierniwo dentystyczne
JP2010520286A (ja) 2007-03-05 2010-06-10 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Ｗｎｔ組成物およびその使用方法
US20110171607A1 (en) 2007-10-25 2011-07-14 The Trustees Of Columbia University In The City Of New York Biopulp
CN102764271B (zh) 2008-02-08 2016-03-02 高露洁-棕榄公司 双组分口腔护理产品
RU2493812C2 (ru) 2008-02-08 2013-09-27 Колгейт-Палмолив Компани Зубной герметик
WO2011062147A1 (ja) * 2009-11-17 2011-05-26 国立大学法人 岡山大学 歯髄細胞から象牙芽細胞への分化誘導方法
US20120329790A1 (en) 2009-11-23 2012-12-27 University Of Medicine And Dentistry Of New Jersey Dentinal Drug Delivery Composition
AU2011213631B2 (en) * 2010-02-08 2015-05-14 Board Of Regents Of The University Of Nebraska Biomineral and metal binding liposomes, their synthesis, and methods of use thereof
WO2012034070A1 (en) 2010-09-09 2012-03-15 The Board Of Trustees Of The Leland Stanford Junior University Use of liposomal wnt compositions to enhance osseointegration
WO2012122081A2 (en) 2011-03-04 2012-09-13 President And Fellows Of Harvard College Dental treatment systems and uses thereof
EP2976044A4 (en) 2013-03-21 2016-11-23 Univ Columbia COMPOSITIONS AND METHODS FOR THE DENTAL GENERATION

Also Published As

Publication number Publication date
WO2016109433A1 (en) 2016-07-07
JP2018502094A (ja) 2018-01-25
US20200046801A1 (en) 2020-02-13
US11260103B2 (en) 2022-03-01
EP3240562A4 (en) 2018-08-15
US10512668B2 (en) 2019-12-24
EP3240562A1 (en) 2017-11-08
US20180000893A1 (en) 2018-01-04
EP3240562B1 (en) 2023-03-22
AU2015374240B2 (en) 2021-11-11
JP6887948B2 (ja) 2021-06-16
AU2015374240A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
Fan et al. Sesamin prevents apoptosis and inflammation after experimental myocardial infarction by JNK and NF-κB pathways
KR102344321B1 (ko) 알츠하이머 질환 치료시 PI4KIIIα 단백질 및 관련 막 단백질 컴플렉스의 적용
EP2851084B1 (en) Modulation of the Vps10p-domain receptors for the treatment of cardiovascular disease
US20080226707A1 (en) WNT compositions and methods of use thereof
JP6565121B2 (ja) 代謝障害を治療する方法
US20230050133A1 (en) Use of liposomal wnt compositions to enhance osseointegration
KR20210117271A (ko) 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
Du et al. Isoflurane promotes phagocytosis of apoptotic neutrophils through AMPK-mediated ADAM17/Mer signaling
US7696160B2 (en) Compositions useful for and methods of modulating angiogenesis
JP2021505611A (ja) 免疫疾患の予防または治療のためのｒｉｐｋ１阻害剤とｉｋｋ阻害剤の組み合わせ
US11260103B2 (en) Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production
JP5481473B2 (ja) 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体
Jiang et al. Adseverin plays a role in osteoclast differentiation and periodontal disease‐mediated bone loss
KR102488987B1 (ko) 알츠하이머 질환을 치료하는데 사용되는 약물 및 치료 표적제를 스크리닝하는 방법
WO2015174443A1 (ja) インターロイキン１α（ＩＬ－１α）を含有する巨核球分化誘導及び血小板産生促進剤
KR20260060365A (ko) 골 및 연골 퇴행의 치료를 위한 뇌 유래 골형성 인자 ccn3의 사용 방법
Bhatia The Role of Secreted Hsp90α in Tissue Repair and Cancer
Harjunen Skin stem cells and tumor growth: functions of collagen XVIII in hair follicle cycling and skin cancer, and Bmx tyrosine kinase in tumor angiogenesis
Elamaa Type XVIII collagen: characterization of the primary structure and expression pattern of different variants in Xenopus laevis, characterization of the human gene structure and analysis of transgenic mice expressing endostatin
HK1208802B (en) Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201222

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240826

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250630

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260209